3M Company (MMM) 2007 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2007. 3M is a diversified global technology company operating in six segments: Industrial and Transportation, Health Care, Display and Graphics, Consumer and Office, Safety, Security and Protection Services, and Electro and Communications. The company employs approximately 76,239 people globally. In 2007, 3M completed the sale of its global branded pharmaceuticals business (finalized in Q1 2007 for Europe and Q4 2006 for other regions) and the Opticom/Canoga traffic detection businesses. The company also announced the acquisition of Aearo Holding Corp. for approximately $1.2 billion, expected to close in early 2008.
Key Financial Metrics
| Metric | 2007 | 2006 | Change |
|---|---|---|---|
| Net Sales | $24.462 billion | $22.923 billion | +6.7% |
| Net Income | $4.096 billion | $3.851 billion | +6.4% |
| Diluted EPS | $5.60 | $5.06 | +10.7% |
| Operating Income | $6.193 billion | $5.696 billion | +8.7% |
| Operating Margin | 25.3% | 24.8% | +0.5 pts |
| Operating Cash Flow | $4.275 billion | $3.839 billion | +11.4% |
| Total Debt | $4.920 billion | $3.553 billion | +38.5% |
| Cash & Equivalents | $1.896 billion | $1.447 billion | +31.0% |
| Debt-to-Capital Ratio | 30% | 26% | N/A |
Note: 2007 results included net gains of $448 million (after-tax) from the sale of businesses and real estate, partially offset by environmental liability increases and restructuring costs.
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales grew 6.7%, driven by a 7.3% increase in local-currency sales. Organic local-currency growth was 4.9%. Divestitures (primarily pharmaceuticals) reduced sales growth by 3.8%.
- Segment Performance:
- Health Care: Sales declined 1.1% due to the pharmaceutical divestiture (-23.7% impact), though remaining businesses grew 18.3% in local currency.
- Safety, Security and Protection Services: Sales grew 15.3% (10.8% local currency), driven by acquisitions and respiratory protection demand.
- Display and Graphics: Sales grew 3.2%, but faced attachment rate pressure in LCD monitors and TVs.
- Cost Structure: Cost of sales increased 1.0 percentage points to 52.1% of sales, largely due to the sale of the low-cost-of-sales pharmaceutical business and higher raw material costs (metals, wood pulp, oil derivatives). SG&A expenses decreased 1.6 percentage points to 20.5% of sales.
- Debt Levels: Total debt increased significantly to $4.92 billion from $3.55 billion, utilized to fund share repurchases and acquisitions.
Guidance, Outlook, and Risks
- Capital Expenditures: Expected to total $1.3 billion to $1.4 billion in 2008.
- Dividends: In February 2008, the Board increased the quarterly dividend by 4.2% to $0.50 per share, marking the 50th consecutive year of dividend increases.
- Share Repurchases: A $7.0 billion authorization was in place through February 2009; approximately $4.1 billion remained available as of year-end 2007.
- Outlook: Management expects raw material costs to remain high in early 2008 with potential moderation later. Display and Graphics margins are expected to decline slightly in 2008 due to pricing pressure.
- Risks:
- Legal Proceedings: Significant exposure to respirator mask/asbestos litigation (approx. 8,750 pending claims) and environmental remediation (PFOA/PFOS compounds). The company increased environmental liabilities by $134 million in 2007.
- Commodity Prices: Volatility in oil, natural gas, and raw materials.
- Currency: Approximately 63% of revenue is international; a strengthening U.S. dollar could negatively impact reported growth.
Investor Verification Checklist
- Pharmaceutical Divestiture Impact: Verify the sustainability of Health Care segment growth excluding the one-time supply agreement benefits and the full impact of the divestiture on future revenue baselines.
- Environmental Liabilities: Review Note 13 for details on the $134 million increase in environmental reserves related to PFOA/PFOS compounds and the potential for future regulatory costs in Minnesota and Alabama.
- Asbestos/Respirator Litigation: Assess the adequacy of the $121 million liability reserve against the $332 million insurance receivable, noting the uncertainty in claim resolution costs and insurer solvency.
- Debt Utilization: Confirm the strategic use of the increased debt load ($1.3 billion net increase) regarding the Aearo acquisition and share buyback program.
- Display and Graphics Margins: Monitor the segment's ability to maintain margins amidst attachment rate losses in the LCD market and competitive pricing pressure.